A bill to amend the Federal Food, Drug, and Cosmetic Act to require drug labeling to include original manufacturer and supply chain information.

S. 3788 would amend federal drug labeling requirements to mandate that pharmaceutical manufacturers include information about the original manufacturer and the complete supply chain on drug labels. This means medications would need to display details about where the drug was originally made and how it moved through distribution channels before reaching consumers.

If enacted, this bill aims to increase transparency in the pharmaceutical supply chain, potentially helping consumers and healthcare providers better understand a drug's origin and distribution history. The requirement would apply to drug labeling under the Federal Food, Drug, and Cosmetic Act. The bill was introduced in February 2026 and received committee hearings in March 2026, but has not yet advanced further in the legislative process.